Information about aerosol generating respiratory therapies: COVID-19
In patients with COVID-19, the use of respiratory therapies that generate aerosolised particles is considered high risk. This is because these therapies are capable of transmitting respiratory viruses, including COVID-19.
Refer to guidance on how to mitigate the risk of these therapies and what alternatives to consider:
- high flow nasal prong oxygen (HFNPO2)
- non-invasive ventilation (CPAP/BIPAP)
- respiratory physiotherapy.
These documents were informed by an evidence review, and developed by experts from the respiratory, intensive care, anaesthetics, paediatrics and infection control disciplines.
Please contact the Respiratory Network team for more information.